Adjuvant Ipilimumab effects survival after high risk lymph node and melanoma resection
Results of an EORTC trial appearing in The Lancet Oncology show that adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, ...
Apr 20, 2015
0
3